Servana (SERV) Q4 2024 earnings summary

Executive summary

• Revenue increased for the ninth consecutive quarter, driven by growth in Denmark and positive demand for Medimi's digital medication management solution.

• Full-year revenue rose 32% year-over-year, with a 39% increase in Q4 compared to the same quarter last year.

• Cost reductions contributed to improved results, but expectations for profitability remain high.

• Strategic review led to a decision to divest the Danish subsidiary and related assets, with ongoing restructuring in Sweden.

• The CEO's contract was terminated as part of restructuring, but he remains during the transition.

Financial highlights

• Q4 net revenue: 1,343 KSEK (up 39% from 970 KSEK in Q4 2023); full-year net revenue: 4,834 KSEK (up 32% from 3,638 KSEK in 2023).

• Q4 result after financial items: -3,076 KSEK (improved from -3,876 KSEK); full-year: -12,526 KSEK (improved from -14,250 KSEK).

• Operating costs for the year decreased by 4% to -17,144 KSEK.

• Cash and cash equivalents at year-end: 5,183 KSEK (down from 12,309 KSEK).

• Equity at year-end: 6,555 KSEK (down from 13,751 KSEK); equity ratio: 50% (down from 66%).

Outlook and guidance

• Danish operations expected to reach profitability within 12 months; process to divest Danish subsidiary initiated.

• Exploring a reverse acquisition to bring in new business and owners.

• Restructuring in Sweden includes staff reductions and focus on core assets.